Levy Adam D. 4
4 · Acrivon Therapeutics, Inc. · Filed Jan 16, 2026
Insider Transaction Report
Form 4
Levy Adam D.
Chief Financial Officer
Transactions
- Purchase
Common Stock
[F1]2026-01-14$1.70/sh+8,832$14,999→ 20,983 total
Footnotes (1)
- [F1]The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4.
Signature
/s/ Adam D. Levy|2026-01-16